ROPIVACAINE HYDROCHLORIDE
Clinical safety rating: safe
Animal studies have demonstrated safety
Ropivacaine is an amide-type local anesthetic that reversibly blocks nerve impulse propagation by inhibiting sodium ion influx via voltage-gated sodium channels in neuronal cell membranes.
| Metabolism | Primarily hepatic metabolism via CYP1A2 and CYP3A4 isoforms to 3-hydroxy-ropivacaine and other metabolites. |
| Excretion | Renal: 86% as metabolites and unchanged drug (primarily 3-hydroxy-ropivacaine and 4-hydroxy-ropivacaine glucuronides). Fecal: <1%. Biliary: minor. |
| Half-life | Terminal elimination half-life: 1.8–2.7 hours (mean 2.0 h) in adults. In neonates, prolonged to 3–6 hours due to immature hepatic clearance. |
| Protein binding | 94% bound to alpha-1-acid glycoprotein (AAG) and, to a lesser extent, albumin. Binding is concentration-dependent and saturable. |
| Volume of Distribution | Vd: 0.84 L/kg (adults). In neonates: 3–5 L/kg due to increased extracellular fluid volume and reduced protein binding. |
| Bioavailability | Epidural: 100% (systemic absorption). No oral formulation. Intravenous: 100%. Intrathecal: 100% (but rapid vascular uptake). |
| Onset of Action | Epidural: 10–20 minutes for sensory block. Peripheral nerve block: 15–30 minutes. Infiltration: 1–5 minutes. Intrathecal: 5–10 minutes. |
| Duration of Action | Epidural: 2–4 hours (sensory block). Peripheral nerve block: 4–8 hours (up to 12 h with epinephrine). Infiltration: 2–6 hours. Dose-dependent. |
0.2% to 0.5% solution; epidural: 15-30 mg bolus, then 6-14 mg/hour infusion; peripheral nerve block: 0.5% solution, 20-30 mL; local infiltration: 0.2% solution, up to 200 mg total.
| Dosage form | SOLUTION |
| Renal impairment | No specific dose adjustment required; caution in severe renal impairment (GFR < 30 mL/min) due to potential accumulation of metabolites. |
| Liver impairment | Child-Pugh Class A: No adjustment; Class B: Reduce dose by 50% and monitor closely; Class C: Contraindicated due to reduced clearance. |
| Pediatric use | Caudal block: 0.2% solution, 1 mL/kg (max 2 mg/kg); epidural: 0.1-0.2% solution, 0.5-1 mL/kg bolus then 0.1-0.4 mL/kg/hour infusion; maximum dose: 2 mg/kg. |
| Geriatric use | Elderly patients may require reduced doses due to decreased clearance; start at lower end of dosing range and titrate carefully; monitor for cardiovascular and neurological toxicity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other local anesthetics or drugs that cause methemoglobinemia can have additive effects Can cause CNS toxicity and methemoglobinemia.
| Breastfeeding | Ropivacaine is excreted into breast milk in small amounts. The M/P ratio (milk to plasma concentration) is approximately 0.6. Oral bioavailability in infants is low due to first-pass metabolism. Therefore, it is considered compatible with breastfeeding. Caution is advised with repeated large doses. |
| Teratogenic Risk | Ropivacaine crosses the placenta. No teratogenic effects have been observed in animal studies. In humans, use during the first trimester is generally not associated with major malformations based on limited data. During the second and third trimesters, local anesthetics can cause fetal bradycardia and acidosis, particularly with paracervical block. Risk of neonatal CNS depression if high doses are administered near term. |
■ FDA Black Box Warning
None officially required by FDA, but risk of cardiac arrest and severe adverse effects with unintentional intravascular or high-dose administration exists.
| Common Effects | Hypotension |
| Serious Effects |
["Hypersensitivity to ropivacaine or other amide-type local anesthetics","Severe hypotension or cardiogenic shock","Inflammatory or infected injection site","Intravenous regional anesthesia (Bier block)"]
| Precautions | ["Risk of systemic toxicity (CNS and cardiac) with high doses or unintentional intravascular injection","Use with caution in patients with hepatic impairment, severe renal disease, or hypovolemia","May cause methemoglobinemia in rare cases","Monitor for signs of local anesthetic systemic toxicity (LAST) during administration"] |
Loading safety data…
| Fetal Monitoring | Continuous fetal heart rate monitoring during labor epidural administration. Maternal blood pressure monitoring for hypotension. Monitor for signs of systemic toxicity (CNS and cardiovascular) in both mother and fetus. For prolonged or high-dose infusions, monitor maternal and fetal acid-base status. |
| Fertility Effects | No specific studies on fertility effects in humans. Animal studies at doses equivalent to the maximum recommended human dose showed no impairment of fertility. Ropivacaine is not expected to significantly affect fertility. |